| Dr Chukwudi Emmanuel Nwodo, MD | |
|
100 Hospital Dr, Lebanon, MO 65536-9210 | |
| (417) 533-6350 | |
| Not Available |
| Full Name | Dr Chukwudi Emmanuel Nwodo |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 100 Hospital Dr, Lebanon, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760672497 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2010019787 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Phelps County Regional Medical Center | Rolla, MO | Hospital |
| Mercy St Francis Hospital | Mountain view, MO | Hospital |
| Mercy Hospital Springfield | Springfield, MO | Hospital |
| Ozarks Medical Center | West plains, MO | Hospital |
| Mercy Hospital - Aurora | Aurora, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy St Francis Hospital | 7810806643 | 9 |
| Ozarks Medical Center | 3870491863 | 142 |
| Phelps County Regional Medical Center | 2860391158 | 78 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Phelps County Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891766051 PECOS PAC ID: 2860391158 Enrollment ID: O20040106000405 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Mercy Hospital Cassville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285676932 PECOS PAC ID: 8820999139 Enrollment ID: O20040120000164 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Mercy St Francis Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023053477 PECOS PAC ID: 7810806643 Enrollment ID: O20040120000229 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Ozarks Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831115641 PECOS PAC ID: 3870491863 Enrollment ID: O20040209001035 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Mercy Hospital Aurora |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467543090 PECOS PAC ID: 9436063211 Enrollment ID: O20040727000335 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Mercy St Francis Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1023053477 PECOS PAC ID: 7810806643 Enrollment ID: O20061104000139 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Mercy Hospital Aurora |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1467543090 PECOS PAC ID: 9436063211 Enrollment ID: O20061104000261 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Citizens Memorial Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558548818 PECOS PAC ID: 2769574433 Enrollment ID: O20070827000044 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Mercy Hospital Cassville |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1285676932 PECOS PAC ID: 8820999139 Enrollment ID: O20100118000033 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Entity Name | Camden Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003181637 PECOS PAC ID: 2961665369 Enrollment ID: O20120523000037 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chukwudi Emmanuel Nwodo, MD 4428 E Ambrose Dr, Springfield, MO 65802-2446 Ph: (302) 465-5442 | Dr Chukwudi Emmanuel Nwodo, MD 100 Hospital Dr, Lebanon, MO 65536-9210 Ph: (417) 533-6350 |
News Archive
In the last few decades, dozens of new breast cancer drugs - from chemotherapies to targeted compounds - have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer?
OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.
Researchers have charted the complex molecular biology of uterine carcinosarcoma, a rare and aggressive gynecologic cancer, according to a study published on March 13 in Cancer Cell.
Researchers at The Ohio State University Wexner Medical Center are trying to help patients who have suffered a stroke to improve arm movement by stimulating the brain using a device called a Transcranial Magnetic Stimulator (TMS). By using TMS to reduce brain activity on the side that was not injured by the stroke, the injured side may have a better chance of recovering.
› Verified 2 days ago
Rosana Mendoza Lim-javate, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 341 Hospital Dr., Family Health Associates, P.c., Lebanon, MO 65536 Phone: 417-588-3918 | |
Dr. Sailaja Tummala, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 755 Cowan Drive, Lebanon, MO 65536 Phone: 417-532-2805 Fax: 417-532-2865 | |
Dr. John C. Tabb, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 331 Hospital Dr, Suite C, Lebanon, MO 65536 Phone: 417-533-6500 Fax: 417-533-6555 | |
Jolene Ann Ostwinkle, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 341 Hospital Dr, Lebanon, MO 65536 Phone: 417-532-7850 Fax: 417-532-2451 | |
Dr. Jennifer S. Powell, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 120 Hospital Dr, Suite 100, Lebanon, MO 65536 Phone: 417-533-6751 Fax: 417-533-6755 | |
Dr. Philip V. Mitchell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Hospital Dr, Suite 100, Lebanon, MO 65536 Phone: 417-533-6751 Fax: 417-533-6755 | |
Dr. Mary A Kurek, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 510 Highway 32, Lebanon, MO 65536 Phone: 417-269-2278 Fax: 417-269-2274 |